🚀 VC round data is live in beta, check it out!
Natco Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Natco Pharma and similar public comparables like Eris Lifesciences, Nippon Shinyaku, Ocular Therapeutix, Hepalink and more.
Natco Pharma Overview
About Natco Pharma
Natco Pharma Ltd is a drug manufacturing company. Natco aims to make specialty medicines accessible to all by manufacturing niche pharmaceutical products backed by its research and development capabilities. While the vast majority of the company's revenue is generated in India, the company looks internationally for growth opportunities. The company maintains a presence in Oncology and Hepatology treatment areas. Natco's active pharmaceutical ingredient segment APIs forms a core part of the company's business. The company operates in two different business segments: pharmaceuticals and agrochemicals. It derives maximum revenue from Pharmaceuticals Segment.
Founded
1981
HQ
Employees
5.0K
Website
Sectors
Financials (LTM)
EV
$2B
Natco Pharma Financials
Natco Pharma reported last 12-month revenue of $430M and EBITDA of $157M.
In the same LTM period, Natco Pharma generated $351M in gross profit, $157M in EBITDA, and $137M in net income.
Revenue (LTM)
Natco Pharma P&L
In the most recent fiscal year, Natco Pharma reported revenue of $519M and EBITDA of $273M.
Natco Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $430M | XXX | $519M | XXX | XXX | XXX |
| Gross Profit | $351M | XXX | $381M | XXX | XXX | XXX |
| Gross Margin | 82% | XXX | 73% | XXX | XXX | XXX |
| EBITDA | $157M | XXX | $273M | XXX | XXX | XXX |
| EBITDA Margin | 36% | XXX | 53% | XXX | XXX | XXX |
| EBIT Margin | 33% | XXX | 46% | XXX | XXX | XXX |
| Net Profit | $137M | XXX | $221M | XXX | XXX | XXX |
| Net Margin | 32% | XXX | 43% | XXX | XXX | XXX |
| Net Debt | — | — | $16M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Natco Pharma Stock Performance
Natco Pharma has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Natco Pharma's stock price is $12.03.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | 3.2% | XXX | XXX | XXX | $1.24 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNatco Pharma Valuation Multiples
Natco Pharma trades at 4.1x EV/Revenue multiple, and 11.1x EV/EBITDA.
EV / Revenue (LTM)
Natco Pharma Financial Valuation Multiples
As of April 19, 2026, Natco Pharma has market cap of $2B and EV of $2B.
Equity research analysts estimate Natco Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Natco Pharma has a P/E ratio of 15.8x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 4.1x | XXX | 3.4x | XXX | XXX | XXX |
| EV/EBITDA | 11.1x | XXX | 6.4x | XXX | XXX | XXX |
| EV/EBIT | 12.3x | XXX | 7.2x | XXX | XXX | XXX |
| EV/Gross Profit | 5.0x | XXX | 4.6x | XXX | XXX | XXX |
| P/E | 15.8x | XXX | 9.7x | XXX | XXX | XXX |
| EV/FCF | 20.3x | XXX | 12.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Natco Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Natco Pharma Margins & Growth Rates
Natco Pharma's revenue in the last 12 month declined by (20%).
Natco Pharma's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
Natco Pharma's rule of 40 is 10% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Natco Pharma's rule of X is (16%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Natco Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (20%) | XXX | (16%) | XXX | XXX | XXX |
| EBITDA Margin | 36% | XXX | 53% | XXX | XXX | XXX |
| EBITDA Growth | (47%) | XXX | (41%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 10% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (16%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 3% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 4% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 8% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 32% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Natco Pharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Natco Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Eris Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Nippon Shinyaku | XXX | XXX | XXX | XXX | XXX | XXX |
| Ocular Therapeutix | XXX | XXX | XXX | XXX | XXX | XXX |
| Hepalink | XXX | XXX | XXX | XXX | XXX | XXX |
| Syndax | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Natco Pharma M&A Activity
Natco Pharma acquired XXX companies to date.
Last acquisition by Natco Pharma was on XXXXXXXX, XXXXX. Natco Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Natco Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialNatco Pharma Investment Activity
Natco Pharma invested in XXX companies to date.
Natco Pharma made its latest investment on XXXXXXXX, XXXXX. Natco Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Natco Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Natco Pharma
| When was Natco Pharma founded? | Natco Pharma was founded in 1981. |
| Where is Natco Pharma headquartered? | Natco Pharma is headquartered in India. |
| How many employees does Natco Pharma have? | As of today, Natco Pharma has over 5K employees. |
| Who is the CEO of Natco Pharma? | Natco Pharma's CEO is Rajeev Nannapaneni. |
| Is Natco Pharma publicly listed? | Yes, Natco Pharma is a public company listed on National Stock Exchange of India. |
| What is the stock symbol of Natco Pharma? | Natco Pharma trades under NATCOPHARM ticker. |
| When did Natco Pharma go public? | Natco Pharma went public in 1995. |
| Who are competitors of Natco Pharma? | Natco Pharma main competitors are Eris Lifesciences, Nippon Shinyaku, Ocular Therapeutix, Hepalink. |
| What is the current market cap of Natco Pharma? | Natco Pharma's current market cap is $2B. |
| What is the current revenue of Natco Pharma? | Natco Pharma's last 12 months revenue is $430M. |
| What is the current revenue growth of Natco Pharma? | Natco Pharma revenue growth (NTM/LTM) is (20%). |
| What is the current EV/Revenue multiple of Natco Pharma? | Current revenue multiple of Natco Pharma is 4.1x. |
| Is Natco Pharma profitable? | Yes, Natco Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Natco Pharma? | Natco Pharma's last 12 months EBITDA is $157M. |
| What is Natco Pharma's EBITDA margin? | Natco Pharma's last 12 months EBITDA margin is 36%. |
| What is the current EV/EBITDA multiple of Natco Pharma? | Current EBITDA multiple of Natco Pharma is 11.1x. |
| What is the current FCF of Natco Pharma? | Natco Pharma's last 12 months FCF is $86M. |
| What is Natco Pharma's FCF margin? | Natco Pharma's last 12 months FCF margin is 20%. |
| What is the current EV/FCF multiple of Natco Pharma? | Current FCF multiple of Natco Pharma is 20.3x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.